NCT01927341View on ClinicalTrials.gov

Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

November 19, 2013

Primary Completion Date

January 25, 2016

Study Completion Date

January 25, 2016

Conditions
Metastatic Colorectal Cancer
Interventions
DRUG

MEK162

Tablet for oral use, 45 mg (three 15 mg tablets), BID

DRUG

Panitumumab

Intravenous infusion, 20mg/ml concentrate solution for infusion, Q2W (Days 1 and 15 of every cycle)

Trial Locations (8)

3000

Pfizer Investigative Site, Leuven

20162

Pfizer Investigative Site, Milan

31059

Pfizer Investigative Site, Toulouse

90033

Memorial Sloan Kettering Cancer Center Oncology Dept, New York

90095

University of California at Los Angeles Dept of Onc, Los Angeles

M5G 2M9

Pfizer Investigative Site, Toronto

1066 CX

Pfizer Investigative Site, Amsterdam

08035

Pfizer Investigative Site, Barcelona

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01927341 - Phase Ib/II Study of Efficacy and Safety of MEK162 and Panitumumab, in Adult mCRC Patients With Mutant or Wild-type RAS Tumors | Biotech Hunter | Biotech Hunter